EZZ Life Science Holdings Limited
EZZ Life Science Holdings Limited (EZZ.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for EZZ Life Science Holdings Limited (EZZ.AX), covering cash flow, earnings, and balance sheets.
EZZ Life Science Holdings Limited (EZZ.AX) Income Statement & Financial Overview
Access detailed annual and quarterly income data for EZZ Life Science Holdings Limited EZZ.AX financial performance.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $44.75M | $21.70M | $22.02M | $11.02M |
| Cost of Revenue | $10.01M | $7.14M | $5.34M | $2.32M |
| Gross Profit | $34.73M | $14.56M | $16.68M | $8.70M |
| Gross Profit Ratio | $0.78 | $0.67 | $0.76 | $0.79 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $26.51M | $13.06M | $13.82M | $6.73M |
| Operating Expenses | $26.51M | $13.06M | $13.82M | $7.14M |
| Total Costs & Expenses | $36.52M | $20.20M | $19.16M | $9.46M |
| Interest Income | $148808.00 | $46930.00 | $18398.00 | $5244.00 |
| Interest Expense | $10528.00 | $14226.00 | $7911.00 | $0.00 |
| Depreciation & Amortization | $200233.00 | $191304.00 | $123843.00 | $6230.00 |
| EBITDA | $8.64M | $1.73M | $3.25M | $1.45M |
| EBITDA Ratio | $0.19 | $0.08 | $0.14 | $0.13 |
| Operating Income | $8.22M | $1.49M | $2.86M | $1.45M |
| Operating Income Ratio | $0.18 | $0.07 | $0.13 | $0.13 |
| Other Income/Expenses (Net) | $209911.00 | $32704.00 | $260640.00 | $112820.00 |
| Income Before Tax | $8.43M | $1.53M | $3.12M | $1.56M |
| Income Before Tax Ratio | $0.19 | $0.07 | $0.14 | $0.14 |
| Income Tax Expense | $2.61M | $383724.00 | $791642.00 | $395821.00 |
| Net Income | $5.82M | $1.14M | $2.33M | $1.17M |
| Net Income Ratio | $0.13 | $0.05 | $0.11 | $0.11 |
| EPS | $0.13 | $0.03 | $0.05 | $0.03 |
| Diluted EPS | $0.13 | $0.03 | $0.05 | $0.03 |
| Weighted Avg Shares Outstanding | $43.46M | $42.70M | $42.70M | $42.66M |
| Weighted Avg Shares Outstanding (Diluted) | $43.46M | $42.70M | $42.70M | $42.65M |
Financial performance has remained strong, with revenue growing from $11.02M in Q3 2023 to $44.75M in Q4 2024. Gross profit continued to perform well, with margins at 78% in the latest quarter. Operating income reached $8.22M in Q4 2024, holding a steady 18% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $8.64M. Net income rose to $5.82M, keeping EPS at $0.13. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan